[1] Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019 Jan;18(1):41-58. doi: 10.1038/nrd.2018.168. Epub 2018 Oct 12. PMID: 30310233.
[2] Sleire L, Førde HE, Netland IA, Leiss L, Skeie BS, Enger PØ. Drug repurposing in cancer. Pharmacol Res. 2017 Oct;124:74-91. doi: 10.1016/j.phrs.2017.07.013. Epub 2017 Jul 13. PMID: 28712971.
[3] Kumar A, Singh UK, Kini SG, Garg V, Agrawal S, Tomar PK, Pathak P, Chaudhary A, Gupta P, Malik A. JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases. Future Med Chem. 2015;7(15):2065-86. doi: 10.4155/fmc.15.132. Epub 2015 Oct 27. PMID: 26505831.
[4] Rosen AW, Degett TH, Gögenur I. [Individualized treatment of colon cancer]. Ugeskr Laeger. 2016 Aug 1;178(31):V11150916. Danish. PMID: 27506915.
[5] Fotheringham S, Mozolowski GA, Murray EMA, Kerr DJ. Challenges and solutions in patient treatment strategies for stage II colon cancer. Gastroenterol Rep (Oxf). 2019 Jun;7(3):151-161. doi: 10.1093/gastro/goz006. Epub 2019 Mar 11. PMID: 31217978; PMCID: PMC6573795.
[6] Jonas S, Wild C, Schamberger C. "Screening" in speziellen Situationen. Prädiktive humangenetische Diagnostik bei hereditärem Mamma- und Kolorektalkarzinom ["Screening" in special situations. Assessing predictive genetic screening for hereditary breast and colorectal cancer]. Z Arztl Fortbild Qualitatssich. 2003 Feb;97(1):67-71. German. PMID: 12669692.
[7] Neuwirtová R. Povede poznávání mechanizmu apoptózy k novým terapeutickým postupům? [Will knowledge of the mechanisms of apoptosis lead to new therapeutic procedures?]. Cas Lek Cesk. 2001 Aug 2;140(15):460-4. Czech. PMID: 11569166.
[8] Ucker DS, Levine JS. Exploitation of Apoptotic Regulation in Cancer. Front Immunol. 2018 Feb 27;9:241. doi: 10.3389/fimmu.2018.00241. PMID: 29535707; PMCID: PMC5835066.
[9] Huerta S, Goulet EJ, Livingston EH. Colon cancer and apoptosis. Am J Surg. 2006 Apr;191(4):517-26. doi: 10.1016/j.amjsurg.2005.11.009. PMID: 16531147.
[10] Dunbar JP, Sulpice R, Dugon MM. The kiss of (cell) death: can venom-induced immune response contribute to dermal necrosis following arthropod envenomations? Clin Toxicol (Phila). 2019 Aug;57(8):677-685. doi: 10.1080/15563650.2019.1578367. Epub 2019 Feb 26. PMID: 30806093.
[11] Patel HJ, Patel BM. TNF-α and cancer cachexia: Molecular insights and clinical implications. Life Sci. 2017 Feb 1;170:56-63. doi: 10.1016/j.lfs.2016.11.033. Epub 2016 Dec 3. PMID: 27919820.
[12] Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019 Jan;18(1):41-58. doi: 10.1038/nrd.2018.168. Epub 2018 Oct 12. PMID: 30310233.
[13] Parvathaneni V, Kulkarni NS, Muth A, Gupta V. Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discov Today. 2019 Oct;24(10):2076-2085. doi: 10.1016/j.drudis.2019.06.014. Epub 2019 Jun 22. PMID: 31238113.
[14] Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol Res. 2019 Jun;144:19-50. doi: 10.1016/j.phrs.2019.03.006. Epub 2019 Mar 13. PMID: 30877063.
[15] Sleire L, Førde HE, Netland IA, Leiss L, Skeie BS, Enger PØ. Drug repurposing in cancer. Pharmacol Res. 2017 Oct;124:74-91. doi: 10.1016/j.phrs.2017.07.013. Epub 2017 Jul 13. PMID: 28712971.
[16] Conrad M, Angeli JP, Vandenabeele P, Stockwell BR. Regulated necrosis: disease relevance and therapeutic opportunities. Nat Rev Drug Discov. 2016 May;15(5):348-66. doi: 10.1038/nrd.2015.6. Epub 2016 Jan 18. PMID: 26775689; PMCID: PMC6531857.
[17] Wang S, Zhou D, Xu Z, Song J, Qian X, Lv X, Luan J. Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect. Curr Drug Targets. 2019;20(11):1180-1202. doi: 10.2174/1389450120666190402145325. PMID: 30947670.
[18] Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000 Oct 13;103(2):239-52. doi: 10.1016/s0092-8674(00)00116-1. PMID: 11057897.
[19] Uitdehaag JC, Verkaar F, Alwan H, de Man J, Buijsman RC, Zaman GJ. A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Br J Pharmacol. 2012 Jun;166(3):858-76. doi: 10.1111/j.1476-5381.2012.01859.x. PMID: 22250956; PMCID: PMC3417414.
[20] Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002 Dec 6;298(5600):1911-2. doi: 10.1126/science.1072682. PMID: 12471242.
[21] Yao RQ, Ren C, Xia ZF, Yao YM. Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles. Autophagy. 2021 Feb;17(2):385-401. doi: 10.1080/15548627.2020.1725377. Epub 2020 Feb 12. PMID: 32048886; PMCID: PMC8007140.
[22] Chen J, Ye C, Wan C, Li G, Peng L, Peng Y, Fang R. The Roles of c-Jun N-Terminal Kinase (JNK) in Infectious Diseases. Int J Mol Sci. 2021 Sep 6;22(17):9640. doi: 10.3390/ijms22179640. PMID: 34502556; PMCID: PMC8431791.
[23] Jia Y, Wang F, Guo Q, Li M, Wang L, Zhang Z, Jiang S, Jin H, Chen A, Tan S, Zhang F, Shao J, Zheng S. Curcumol induces RIPK1/RIPK3 complex-dependent necroptosis via JNK1/2-ROS signaling in hepatic stellate cells. Redox Biol. 2018 Oct;19:375-387. doi: 10.1016/j.redox.2018.09.007. Epub 2018 Sep 7. PMID: 30237126; PMCID: PMC6142373.
[24] Valasek MA, Repa JJ. The power of real-time PCR. Adv Physiol Educ. 2005 Sep;29(3):151-9. doi: 10.1152/advan.00019.2005. PMID: 16109794.
[25] Yue Y, Zhang Q, Wu S, Wang S, Cui C, Yu M, Sun Z. Identification of key genes involved in JAK/STAT pathway in colorectal cancer. Mol Immunol. 2020 Dec;128:287-297. doi: 10.1016/j.molimm.2020.10.007. Epub 2020 Nov 25. PMID: 33248399.
[26] Hnasko TS, Hnasko RM. The Western Blot. Methods Mol Biol. 2015;1318:87-96. doi: 10.1007/978-1-4939-2742-5_9. PMID: 26160567.
[27] Hinderer EW 3rd, Moseley HNB. GOcats: A tool for categorizing Gene Ontology into subgraphs of user-defined concepts. PLoS One. 2020 Jun 11;15(6):e0233311. doi: 10.1371/journal.pone.0233311. PMID: 32525872; PMCID: PMC7289357.
[28] Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. doi: 10.1093/nar/gkw1092. Epub 2016 Nov 28. PMID: 27899662; PMCID: PMC5210567.
[29] Andrade C. The P Value and Statistical Significance: Misunderstandings, Explanations, Challenges, and Alternatives. Indian J Psychol Med. 2019 May-Jun;41(3):210-215. doi: 10.4103/IJPSYM.IJPSYM_193_19. PMID: 31142921; PMCID: PMC6532382.
[30] Lee EW, Seo J, Jeong M, Lee S, Song J. The roles of FADD in extrinsic apoptosis and necroptosis. BMB Rep. 2012 Sep;45(9):496-508. doi: 10.5483/bmbrep.2012.45.9.186. PMID: 23010170.
[31] Sosna J, Voigt S, Mathieu S, Lange A, Thon L, Davarnia P, Herdegen T, Linkermann A, Rittger A, Chan FK, Kabelitz D, Schütze S, Adam D. TNF-induced necroptosis and PARP-1-mediated necrosis represent distinct routes to programmed necrotic cell death. Cell Mol Life Sci. 2014 Jan;71(2):331-48. doi: 10.1007/s00018-013-1381-6. Epub 2013 Jun 13. PMID: 23760205; PMCID: PMC3889832.
[32] Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz MA, Yuan J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005 Jul;1(2):112-9. doi: 10.1038/nchembio711. Epub 2005 May 29. Erratum in: Nat Chem Biol. 2005 Sep;1(4):234. PMID: 16408008.
[33] Popa DS, Bigman G, Rusu ME. The Role of Vitamin K in Humans: Implication in Aging and Age-Associated Diseases. Antioxidants (Basel). 2021 Apr 6;10(4):566. doi: 10.3390/antiox10040566. PMID: 33917442; PMCID: PMC8067486.
[34] He S, Wang L, Miao L, Wang T, Du F, Zhao L, Wang X. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell. 2009 Jun 12;137(6):1100-11. doi: 10.1016/j.cell.2009.05.021. PMID: 19524512.
[35] Holbrook J, Lara-Reyna S, Jarosz-Griffiths H, McDermott M. Tumour necrosis factor signalling in health and disease. F1000Res. 2019 Jan 28;8:F1000 Faculty Rev-111. doi: 10.12688/f1000research.17023.1. PMID: 30755793; PMCID: PMC6352924.
[36] Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180-210. doi: 10.1159/000289205. Epub 2010 Feb 18. PMID: 20173395.
[37] Pistritto G, Trisciuoglio D, Ceci C, Garufi A, D'Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 2016 Apr;8(4):603-19. doi: 10.18632/aging.100934. PMID: 27019364; PMCID: PMC4925817.
[38] Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, Yang H, Samadi AK, Russo GL, Spagnuolo C, Ray SK, Chakrabarti M, Morre JD, Coley HM, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich WG, Yang X, Boosani CS, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Keith WN, Bilsland A, Halicka D, Nowsheen S, Azmi AS. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. 2015 Dec;35 Suppl(0):S78-S103. doi: 10.1016/j.semcancer.2015.03.001. Epub 2015 Apr 28. PMID: 25936818; PMCID: PMC4720504.
[39] Sleire L, Førde HE, Netland IA, Leiss L, Skeie BS, Enger PØ. Drug repurposing in cancer. Pharmacol Res. 2017 Oct;124:74-91. doi: 10.1016/j.phrs.2017.07.013. Epub 2017 Jul 13. PMID: 28712971.
[40] Lamson DW, Plaza SM. The anticancer effects of vitamin K. Altern Med Rev. 2003 Aug;8(3):303-18. PMID: 12946240.
[41] Semkova S, Zhelev Z, Miller T, Sugaya K, Aoki I, Higashi T, Bakalova R. Menadione/Ascorbate Induces Overproduction of Mitochondrial Superoxide and Impairs Mitochondrial Function in Cancer: Comparative Study on Cancer and Normal Cells of the Same Origin. Anticancer Res. 2020 Apr;40(4):1963-1972. doi: 10.21873/anticanres.14151. PMID: 32234885.
[42] Calderon PB, Cadrobbi J, Marques C, Hong-Ngoc N, Jamison JM, Gilloteaux J, Summers JL, Taper HS. Potential therapeutic application of the association of vitamins C and K3 in cancer treatment. Curr Med Chem. 2002 Dec;9(24):2271-85. doi: 10.2174/0929867023368674. PMID: 12470246.
[43] Semkova S, Zhelev Z, Miller T, Sugaya K, Aoki I, Higashi T, Bakalova R. Menadione/Ascorbate Induces Overproduction of Mitochondrial Superoxide and Impairs Mitochondrial Function in Cancer: Comparative Study on Cancer and Normal Cells of the Same Origin. Anticancer Res. 2020 Apr;40(4):1963-1972. doi: 10.21873/anticanres.14151. PMID: 32234885.
[44] Kishore C, Sundaram S, Karunagaran D. Vitamin K3 (Menadione) suppresses epithelial-mesenchymal-transition and Wnt signaling pathway in human colorectal cancer cells. Chem Biol Interact. 2019 Aug 25;309:108725. doi: 10.1016/j.cbi.2019.108725. Epub 2019 Jun 22. PMID: 31238027.